Respondents were asked whether they have used GLP-1 drugs and for what purpose, with their answer impacting which questions they were subsequently asked.
Meta-analysis of randomized controlled trials shows L-carnitine supplementation significantly reduces CRP (weighted mean difference -1.23 mg/L), IL-6 (-0.85 pg/dL), and TNF- (-0.37 pg/dL), with greater effects observed in studies exceeding 12 weeks duration.[4] In obese patients, L-carnitine combined with synbiotics reduced IL-6 by 34%, hs-CRP by 10%, TNF- by 19%, and malondialdehyde by 22%.[5] L-carnitine also improves inflammatory markers in chronic kidney disease, cardiovascular disease, and metabolic conditions.[6] Acetyl-L-carnitine offers distinct advantages for neuroinflammation through multiple mechanisms beyond simple carnitine delivery
2025, doi: 10.1001/jama.2025.24288
Given that all-cause mortality differed slightly between groups, this may have influenced the estimated risk of VTE
doi: 10.3390/biology14081081 510 VerhoevenVRenardNMakarAVan RoyenPBogersJPLardonFet al
